- Home
- KNDI vs APLT Comparison
KNDI vs APLT Comparison
Compare KNDI & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KNDI
- APLT
- Stock Information
- Founded
- KNDI 2002
- APLT 2016
- Country
- KNDI China
- APLT United States
- Employees
- KNDI N/A
- APLT N/A
- Industry
- KNDI Auto Manufacturing
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- KNDI Consumer Discretionary
- APLT Health Care
- Exchange
- KNDI Nasdaq
- APLT Nasdaq
- Market Cap
- KNDI 96.3M
- APLT 44.0M
- IPO Year
- KNDI N/A
- APLT 2019
- Fundamental
- Price
- KNDI $1.20
- APLT $0.41
- Analyst Decision
- KNDI
- APLT Buy
- Analyst Count
- KNDI 0
- APLT 7
- Target Price
- KNDI N/A
- APLT $6.10
- AVG Volume (30 Days)
- KNDI 109.2K
- APLT 2.6M
- Earning Date
- KNDI 08-15-2025
- APLT 08-06-2025
- Dividend Yield
- KNDI N/A
- APLT N/A
- EPS Growth
- KNDI N/A
- APLT N/A
- EPS
- KNDI N/A
- APLT N/A
- Revenue
- KNDI $127,569,613.00
- APLT $265,000.00
- Revenue This Year
- KNDI N/A
- APLT $1,768.13
- Revenue Next Year
- KNDI N/A
- APLT $292.85
- P/E Ratio
- KNDI N/A
- APLT N/A
- Revenue Growth
- KNDI 3.21
- APLT N/A
- 52 Week Low
- KNDI $0.89
- APLT $0.30
- 52 Week High
- KNDI $2.07
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- KNDI 52.54
- APLT 58.87
- Support Level
- KNDI $1.09
- APLT $0.32
- Resistance Level
- KNDI $1.17
- APLT $0.36
- Average True Range (ATR)
- KNDI 0.07
- APLT 0.04
- MACD
- KNDI 0.01
- APLT 0.01
- Stochastic Oscillator
- KNDI 61.23
- APLT 94.92
About KNDI Kandi Technologies Group Inc
Kandi Technologies Group Inc is engaged in developing, manufacturing, and commercializing fully electric vehicle products and related technologies. Its products mainly consist of EV parts, EV products, and off-road vehicles, including All-Terrain Vehicles (ATVs), UTVs, go-karts, electric scooters, electric self-balancing scooters, and associated parts, and Lithium-ion cells, etc. The company generates maximum revenue from the sale of Off-road vehicles and associated parts. Geographically, it derives maximum revenue from the United States and other countries, followed by China.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.